Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | APG-2575 + Olverembatinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
APG-2575 | APG 2575|APG2575|Lisaftoclax | BCL2 inhibitor 27 | APG-2575 is a small molecule that inhibits BCL-2, potentially resulting in increased apoptosis and enhanced antitumor activity in combination with other agents (PMID: 32093809, PMID: 37074726). | |
Olverembatinib | HQP 1351|HQP-1351|GZD824 dimesylate|GZD824|HQP1351 | ABL1 Inhibitor 8 FGFR1 Inhibitor 28 FLT3 Inhibitor 69 KIT Inhibitor 57 PDGFR-alpha Inhibitor 9 | Olverembatinib (HQP1351) is a third-generation BCR-ABL inhibitor and multikinase inhibitor that inhibits KIT, ABL1, FGFR1, FLT3, and PDGFRA (PMID: 32247263), which potentially induces apoptosis, and inhibits tumor cell growth, migration, and invasion (PMID: 31673329). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 exon 14 ins | acute myeloid leukemia | predicted - sensitive | APG-2575 + Olverembatinib | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, combination treatment with Olverembatinib (HQP1351) and APG-2575 induced apoptosis to a greater degree than either therapy alone in acute myeloid leukemia cells harboring FLT3-ITD in culture, and resulted in a synergistic tumor burden reduction in a patient-derived xenograft (PDX) model of acute myeloid leukemia harboring FLT3-ITD and inhibited tumor growth in a cell line xenograft model with a T/C ratio of 2.8% (PMID: 34710737). | 34710737 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|